DNA methylation biomarkers and their utility for solid cancer diagnostics

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Cellular DNA methylation undergoes significant alterations during cancer development, characterized by gene promoter hypermethylation and global hypomethylation.
• Aberrant DNA methylation in cancer frequently leads to the silencing of critical genes involved in tumor suppression, cellular growth, regulation, and differentiation.
• Thousands of studies have documented gene methylation in cancer, linking it to clinical status, outcomes, and treatment responses, with emerging epigenomic data.

Purpose of the Study:

• To review and catalogue commonly methylated genes across six major solid cancers: colorectal, pancreatic, prostate, bladder, breast, and ovarian.
• To identify cancer-specific methylated genes that could serve as more versatile biomarkers.
• To explore the potential of these methylated genes for developing novel cancer diagnostic tools.

Main Methods:

• A comprehensive literature review was conducted focusing on DNA methylation studies in six specific solid cancers.
• Analysis centered on identifying frequently methylated genes within these cancer types.
• Particular attention was given to cataloguing genes methylated uniquely in specific cancers.

Main Results:

• Commonly methylated genes were identified across the six studied solid cancers, providing a catalogue for potential tissue-based biomarker development.
• A subset of methylated genes uniquely associated with particular cancers was highlighted.
• The findings suggest that these unique methylated genes may be more suitable for developing accessible screening methods.

Conclusions:

• The identified commonly and uniquely methylated genes represent promising candidates for future cancer biomarker panels.
• Unique methylated genes hold potential for advancing non-invasive cancer screening through blood or urine tests.
• This research consolidates epigenomic information to guide the development of next-generation cancer diagnostics.